3-chloro-3-ethyl-2-(trifluoromethyl)butane-1-ol | 1569454-56-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-chloro-3-ethyl-2-(trifluoromethyl)butane-1-ol
• 英文别名: 3-chloro-3-methyl-2-(trifluoromethyl)butan-1-ol；3-Chloro-3-methyl-2-(trifluoromethyl)butan-1-ol
• CAS: 1569454-56-3
• 化学式: C₆H₁₀ClF₃O
• 分子量: 190.593
• InChiKey: VULNHCNMCCYXOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  三氟甲烷磺酰氯 、 异戊烯醇 在 dipotassium hydrogenphosphate 、 tris(1,10-phenanthroline)ruthenium(II) dichloride 作用下， 以 乙腈 为溶剂， 反应 15.0h， 以62%的产率得到3-chloro-3-ethyl-2-(trifluoromethyl)butane-1-ol
  参考文献：
  名称：

  Vicinal Difunctionalization of Alkenes: Chlorotrifluoromethylation with CF₃SO₂Cl by Photoredox Catalysis

  摘要：

  Photoredox-catalyzed vicinal chlorotrifluoromethylation of alkene is described. In the presence of Ru(Phen)(3)Cl-2, CF3SO2Cl was used as a source for the CF3 radical and chloride ion under visible light irradiation. Various terminal and internal alkenes were transformed to their vicinal chlorotrifluoromethylated derivatives. Biologically active compounds were applied under the condition to obtain desired products, suggesting that the method could be feasible for late-stage modification in drug discovery.

  DOI：

  10.1021/ol403716t

文献信息

• Vicinal Difunctionalization of Alkenes: Chlorotrifluoromethylation with CF₃SO₂Cl by Photoredox Catalysis
  作者：Se Hwan Oh、Yashwardhan R. Malpani、Neul Ha、Young-Sik Jung、Soo Bong Han

  DOI：10.1021/ol403716t

  日期：2014.3.7

  Photoredox-catalyzed vicinal chlorotrifluoromethylation of alkene is described. In the presence of Ru(Phen)(3)Cl-2, CF3SO2Cl was used as a source for the CF3 radical and chloride ion under visible light irradiation. Various terminal and internal alkenes were transformed to their vicinal chlorotrifluoromethylated derivatives. Biologically active compounds were applied under the condition to obtain desired products, suggesting that the method could be feasible for late-stage modification in drug discovery.